ImmuCell Corporation

ICCC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-216.5K
Depreciation & Amortization
Depreciation $394.3K
Amortization
Stock-Based Compensation $94.1K
Net Cash from Operating Activities $-109.7K
Investing Activities
Capital Expenditures $459.5K
Business Acquisitions
Net Cash from Investing Activities $-215.4K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $100.7K
Net Change in Cash $-224.4K
Free Cash Flow $-569.2K
← Newer Page 3 of 3 Older →